These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28336404)

  • 21. HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.
    Nakano Y; Misawa N; Juarez-Fernandez G; Moriwaki M; Nakaoka S; Funo T; Yamada E; Soper A; Yoshikawa R; Ebrahimi D; Tachiki Y; Iwami S; Harris RS; Koyanagi Y; Sato K
    PLoS Pathog; 2017 May; 13(5):e1006348. PubMed ID: 28475648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.
    Ooms M; Majdak S; Seibert CW; Harari A; Simon V
    J Virol; 2010 Aug; 84(16):7961-9. PubMed ID: 20519396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
    Zhang W; Huang M; Wang T; Tan L; Tian C; Yu X; Kong W; Yu XF
    Cell Microbiol; 2008 Aug; 10(8):1662-75. PubMed ID: 18419775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.
    Kitamura S; Ode H; Nakashima M; Imahashi M; Naganawa Y; Kurosawa T; Yokomaku Y; Yamane T; Watanabe N; Suzuki A; Sugiura W; Iwatani Y
    Nat Struct Mol Biol; 2012 Oct; 19(10):1005-10. PubMed ID: 23001005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.
    Baig TT; Feng Y; Chelico L
    J Virol; 2014 Dec; 88(24):14380-95. PubMed ID: 25275135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent Loss of APOBEC3H Activity during Primate Evolution.
    Garcia EI; Emerman M
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
    Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.
    Letko M; Booiman T; Kootstra N; Simon V; Ooms M
    Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural basis of HIV-1 Vif-mediated E3 ligase targeting of host APOBEC3H.
    Ito F; Alvarez-Cabrera AL; Kim K; Zhou ZH; Chen XS
    Nat Commun; 2023 Aug; 14(1):5241. PubMed ID: 37640699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
    Siu KK; Sultana A; Azimi FC; Lee JE
    Nat Commun; 2013; 4():2593. PubMed ID: 24185281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APOBEC3C Tandem Domain Proteins Create Super Restriction Factors against HIV-1.
    McDonnell MM; Crawford KHD; Dingens AS; Bloom JD; Emerman M
    mBio; 2020 Apr; 11(2):. PubMed ID: 32345636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural APOBEC3C variants can elicit differential HIV-1 restriction activity.
    Anderson BD; Ikeda T; Moghadasi SA; Martin AS; Brown WL; Harris RS
    Retrovirology; 2018 Dec; 15(1):78. PubMed ID: 30558640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stably expressed APOBEC3H forms a barrier for cross-species transmission of simian immunodeficiency virus of chimpanzee to humans.
    Zhang Z; Gu Q; de Manuel Montero M; Bravo IG; Marques-Bonet T; Häussinger D; Münk C
    PLoS Pathog; 2017 Dec; 13(12):e1006746. PubMed ID: 29267382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1.
    Jaguva Vasudevan AA; Hofmann H; Willbold D; Häussinger D; Koenig BW; Münk C
    J Mol Biol; 2017 Apr; 429(8):1171-1191. PubMed ID: 28315663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
    Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
    J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.
    Meissner ME; Willkomm NA; Lucas J; Arndt WG; Aitken SF; Julik EJ; Baliga S; Mansky LM
    J Mol Biol; 2022 Jan; 434(2):167355. PubMed ID: 34774569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. APOBEC3F determinants of HIV-1 Vif sensitivity.
    Land AM; Shaban NM; Evans L; Hultquist JF; Albin JS; Harris RS
    J Virol; 2014 Nov; 88(21):12923-7. PubMed ID: 25142588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.
    Refsland EW; Hultquist JF; Luengas EM; Ikeda T; Shaban NM; Law EK; Brown WL; Reilly C; Emerman M; Harris RS
    PLoS Genet; 2014 Nov; 10(11):e1004761. PubMed ID: 25411794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.